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Clinical Infectious Diseases
Major Article

George N. Coritsidis,1,2,3 Sean Yaphe,4 Ilay Rahkman,1 Teresa Lubowski,2 Carly Munro,1 Ti- Kuang Lee,2 Aaron Stern,1 and Premila Bhat3
1

Department of Nephrology, Elmhurst Hospital Center, Icahn School of Medicine at Mount Sinai, Elmhurst, New York, USA, 2IPRO New York Network 2, Lake Success, NY, New York, USA, 3Atlantis
Dialysis, College Point, NY, New York, USA, and 4Department of Family Medicine, Henry Ford Hospital, Detroit, Michigan, USA

Background. Infections are important complications of end-stage renal disease (ESRD) with few studies having investigated
oral antibiotic use. Inappropriate antibiotic prescribing can contribute to multidrug-resistant organisms and Clostridioides difficile
infections seen in ESRD. This study investigates antibiotic prescribing practices in ESRD across New York State (NYS).
Methods. Retrospective case-control study from 2016 to 2017 of NYS ESRD and non-ESRD patients analyzing Medicare part B
billing codes, 7 days before and 3 days after part D claims. Frequencies of each infection, each antibiotic, dosages, and the antibiotics
associated with infections were assessed using χ 2 analysis. A NYS small dialysis organization comprising approximately 2200 patients
was also analyzed. Outcomes measured were the frequencies of infections and of each antibiotic prescribed. Incidence measures included antibiotics per 1000 and individuals receiving antibiotics per 1000.
Results. A total of 48 100 infections were treated in 35 369 ESRD patients and 2 544 443 infections treated in 3 777 314 nonESRD patients. ESRD patients were younger, male, and African American. ESRD and non-ESRD patients receiving antibiotics was
520.29/1000 and 296.48/1000, respectively (P < .05). The prescription incidence was 1359.95/1000 ESRD vs 673.61/1000 non-ESRD
patients. In 36%, trimethoprim-sulfamethoxazole dosage was elevated by current ESRD guidelines. Top infectious categories included
nonspecific symptoms, skin, and respiratory for ESRD; and respiratory, nonspecific symptoms, and genitourinary in non-ESRD.
Conclusions. This study identifies issues with appropriate antibiotic usage stressing the importance of antibiotic education to
nephrologist and nonnephrologist providers. It provides support for outpatient antibiotic stewardship programs.
Keywords. ESRD; hemodialysis; oral antibiotics; antibiotic stewardship.
Infections are an important complication of end-stage renal
disease (ESRD) representing the second most common cause
of death [1]. In both general and ESRD populations, infectious disease research has focused on the potential overuse
of broad-spectrum antibiotics in the inpatient setting and the
subsequent emergence of bacterial resistance. In hemodialysis,
studies have emphasized bloodstream infections and the excessive use of central venous catheters [2, 3].
Studies investigating outpatient oral antibiotic use are limited, with even fewer pertaining to ESRD. These patients carry
multiple comorbid diagnoses and have higher hospitalization
rates than non-ESRD patients [4, 5]. Given their increased risk
of infection, they are more likely to receive intravenous (IV) and
oral antibiotics compared to non-ESRD patients [6–8].
Prescribing antibiotics in ESRD presents physicians with
additional challenges. Given their impaired renal clearance,
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appropriate prescribing must optimize agent selection, dose,
frequency, and duration for the given infection. Inappropriate
antibiotic use may contribute to the increased prevalence of
multidrug-resistant organisms (MDROs) in ESRD patients, as
well as opportunistic Clostridioides difficile infections (CDIs) [4,
5, 9–11].
A recent study of >19 million antibiotic prescriptions in the
general population indicated that 23.2% were inappropriate,
35.5% were potentially inappropriate, and 28.5% were not associated with a recent diagnosis code [12]. In a review of 2 outpatient hemodialysis units, researchers found that 29.8% of IV
antibiotics were prescribed inappropriately [13]. Additionally,
an Australian observational study of ESRD patients demonstrated that about 29% of oral and 21% of IV antibiotics could
be inappropriate [7].
The current study investigates outpatient oral antibiotic prescribing practices across New York State (NYS), assessing differences between ESRD and non-ESRD patients. Additionally, a
small dialysis organization (SDO) in New York City was examined for a more detailed evaluation of prescribing patterns;
comparing providers affiliated to the SDO to other specialists,
such as in family medicine, emergency department (ED), and
urgent care.
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METHODS
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RESULTS

In 2016–2017, 48 100 antibiotics were prescribed to treat presumed infections in 35 369 ESRD patients enrolled in Medicare
parts B and D. Similarly, 2 544 443 antibiotics were prescribed
for 3 777 314 non-ESRD patients. Since most of the individuals were in both years 2016 and 2017 and may have received
multiple doses of antibiotics, the data are based on the adjusted
numbers of 18 410 ESRD patients and 1 119 897 non-ESRD
patients. These numbers ensured that each person appeared
only once in the data to not create bias in demographic data
(Table 1). ESRD patients tended to be younger and male, with
a significant difference in race driven by the higher African
American profile (Table 1). Incidence proportion of prescriptions of antibiotics per 1000 patients was 520.29 in ESRD and
296.48 in non-ESRD (P < .05; Table 2). Since some individuals
were prescribed multiple antibiotics, the rates of prescriptions

Table 1. Characteristics of End-Stage Renal Disease (ESRD) and NonESRD Populations

ESRDb

Characteristic
Age, mean ± SD

Non-ESRDb

P
Value

18 402a

64.80 ±
14.80

1 119 897a

71.00 ±
12.21

<.001

8330

(45.30)

704 700

(62.90)

<.001

10 072

(54.70)

415 197

(37.10)

Sex
Female
Male
Race/ethnicity
Asian

945

(5.10)

33 680

(3.00)

Black

5931

(32.20)

84 622

(7.60)

Hispanic

1282

(7.00)

28 264

(2.50)

67

(0.40)

1401

(0.10)

North American
Native
Other

588

(3.20)

23 717

(2.10)

Unknown

409

(2.20)

26 818

(2.40)

White

9180

(49.90)

921 395

(82.30)

<.001

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ESRD, end-stage renal disease; SD, standard deviation.
a

Individual patients who have received at least 1 antibiotic prescription in 2016 and 2017 ± SD.

b

From Centers for Medicare and Medicaid Services parts B and D (patients with chronic
kidney disease were excluded from the non-ESRD group).
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Network 2, responsible for all of NYS, is 1 of 18 networks contracted out by the Centers for Medicare and Medicaid Services
(CMS) for monitoring quality and improving ESRD care in the
United States. Island Peer Review Organization (IPRO) is contractually responsible for the 290 dialysis units and >29 000 patients in network 2, NYS. Medicare data were collected from
IPRO for NYS from 1 January 2016 to 31 December 2017 on
both ESRD and non-ESRD outpatient populations enrolled in
Medicare Parts B and D. Patients with chronic kidney disease
were excluded from the non-ESRD group. Medicare part B
International Classification of Diseases, Tenth Revision (ICD-10)
billing codes were analyzed 7 days before and 3 days after a part
D claim was filed for an infectious diagnosis. An infection diagnosis was not part of the inclusion criteria; rather, oral outpatient antibiotic prescriptions were. Specific variables included
any antibiotic prescribed (dose and duration), sex, race, county
of residence, source of prescription (inpatient, outpatient, office, or ED), and ICD-10 billing codes. Current Procedural
Terminology codes were used to divide the database into ESRD
and non-ESRD. By assessing the billing codes associated with
the medications prescribed, as well as the locations of the provider who prescribed them, it was possible to remove inpatient prescriptions. Medications may have been prescribed to
inpatients on their way home and filled at an outpatient pharmacy. Only oral antibiotics were included. Patients <18 years of
age, pregnant, on peritoneal or home hemodialysis, or with a
kidney transplant were excluded. CMS data exclude undocumented patients.
Additional similar clinical data including demographic and
antibiotics (doses prescribed and duration) from 2016 and 2017
were collected from an SDO caring for nearly 2500 patients in
12 New York City and Long Island outpatient dialysis centers.
This cohort is separate and does not include the NYS ESRD and
non-ESRD data. In particular, data included whether the provider was an SDO-affiliated nephrologist, physician assistant, or
nurse practitioner, vs an outside provider (OP): an ED, primary
care, family medicine, or urgent care provider. The provider
specialty was ascertained through the use of National Provider
Identifier numbers. The SDO data include all patients regardless of insurance from their units. Infection diagnoses and
categories were not available from the SDO. Exclusion criteria
were the same as for the NYS analysis. Only patients with ESRD
on hemodialysis that were part of the SDO were included.
To assess infection diagnoses and their respective antibiotic usage, ICD-10 codes were separated into 13 infectious
categories: cardiology, ear/nose/throat, gastrointestinal, genitourinary, lymphatics, musculoskeletal, neurological, ophthalmology, respiratory, skin, systemic, nonspecific symptoms, and
other infections. The specific organism and its type were identified when possible (bacterial, viral, unknown, etc). Infections
were further subcategorized using the full ICD-10 coding

documentation in order to create more specific groupings (eg,
sinusitis, cervicitis, osteomyelitis). Unclear categorizations were
resolved by consensus among the researchers.
Data were analyzed by observing frequencies of each category of infection, each antibiotic, the antibiotics associated with
specific categories of infections, and the varying dosages of each
antibiotic. Using χ 2 testing, the frequencies were compared between ESRD and non-ESRD patients. Incidence of individual
prescriptions per 1000 patients was calculated based on the
total number of patients in their respective groups. As some patients received multiple antibiotic prescriptions during the year,
the incidence of patients receiving antibiotics per 1000 patients
was also calculated.

Table 2. Incidence of Patients Receiving Antibiotics and Incidence of
Prescriptions Administered, Both per 1000 Patients, and the Mean Number
of Days of Antibiotics and Prescriptions per Patienta

Prescription data

ESRD

Non-ESRD

P
Value

520.29

296.48

<.001

Incidence of prescriptions (per 1000
patients)

1359.95

673.61

<.001

Days of antibiotics supplied, mean ± SD

10.30 ± 2.10

8.90 ± 1.74

<.001

No. of prescriptions per patient, mean
± SD

2.20 ± 0.12

2.00 ± 0.32 <.001

Abbreviations: ESRD, end-stage renal disease; SD, standard deviation.
a
From Centers for Medicare and Medicaid Services parts B and D.

were 1359.95 per 1000 ESRD patients vs 673.61 per 1000 nonESRD patients. Antibiotics were supplied from outpatient pharmacies with average treatment duration significantly longer in
ESRD patients (10.3 vs 8.9 days; P < .05; Table 2).
Based on ICD-10 codes, 32.4% of ESRD patients and 29.2%
of non-ESRD patients received antibiotics without an associated infection specific diagnosis, significantly higher in ESRD
(P < .001). The frequency of each infection category is detailed
in Table 3. The 3 most common indications for antibiotics were
nonspecific symptoms, skin infections, and respiratory infections in ESRD, and respiratory infections, nonspecific symptoms, and genitourinary infections in non-ESRD. Fifty-two
percent of prescriptions in ESRD either did not have an associated infection diagnosis or were for viral conditions or nonspecific symptoms.
ESRD patients also received significantly different antibiotics (Supplementary Appendix Table 1). Azithromycin
was most commonly prescribed in both groups, with
Table 3. Categorized Indications for Antibiotics Prescribed Organized by
Percentage in the End-Stage Renal Disease Populationa
ESRD, %

Non-ESRD, %

P Value

No diagnosis

32.42

29.21

<.001

Nonspecific

15.10

15.26

Viral

4.70

1.60

<.001

Skin

14.84

10.16

<.001

Respiratory

14.55

15.89

<.001

GU

6.62

13.48

<.001

GI

6.04

2.14

<.001

Systemic

5.10

1.59

<.001

ENT

2.49

9.51

<.001

Other

1.46

1.35

.05

MSK

0.81

0.64

<.001

Ophthalmology

0.25

0.46

<.001

Lymphatics

0.22

0.26

.06

Cardiology

0.07

0.03

<.001

Neurology

0.04

0.02

.05

.34

Figures in bold are indicators with no clear evidence for bacterial antibiotic use.
Abbreviations: ENT, ear nose and throat; ESRD, end-stage renal disease; GI, gastrointestinal; GU, genitourinary; MSK, musculoskeletal.
a

From the Centers for Medicare and Medicaid Services parts B and D.

DISCUSSION

Our study of antibiotic prescribing patterns in NYS indicates
that ESRD patients received almost twice as many antibiotics
compared to non-ESRD patients (Table 2). Skin infections were
the most common reason for antibiotics in ESRD, compared
to respiratory infections in non-ESRD patients. We also found
significant differences in antibiotic selection in ESRD patients
compared to the general public. Additionally, while the percentages of antibiotic prescriptions between renal and nonrenal
providers were similar in the SDO sample, selection varied
significantly.
Antibiotic overuse and misuse are important factors leading
to antibiotic resistance in the general population [15, 16].
Previous studies examining the effects of IV antibiotic prescriptions have demonstrated higher MDRO infection rates
[10]. Yearly, at least 2 million people are affected by antibioticresistant infections, resulting in up to 23 000 deaths [16, 17].
ESRD patients have multiple comorbidities with hospitalization rates higher than the general population. In just the
first year on dialysis, the incidence of infection-related hospitalizations is 32% [18]. Hospital exposure and inappropriate
antibiotic use contribute to the high prevalence of MDRO colonization and infections in ESRD [5, 9–11]. Not surprisingly,
infections in patients with renal disease are more severe and
carry a higher mortality [18]. Moreover, colonized patients returning to outpatient dialysis can then be sources of transmission [19].
Infection control research in ESRD has emphasized the restriction of central venous catheter use and IV antibiotic selection
Antibiotic Use in Outpatient Dialysis • cid 2021:XX (XX XXXX) • 3
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Incidence of patients prescribed (per
1000 patients)

trimethoprim-sulfamethoxazole (TMP-SMX) and the
fluoroquinolones more often in ESRD. When investigating specific dosages, 36% of TMP-SMX prescriptions were prescribed
at a dose (800–160 mg) higher than that recommended by infectious disease guidelines for renal failure [14]. Figure 1A
and 1B display dosing information for TMP-SMX as well as
the fluoroquinolones. Nitrofurantoin comprised 1.28% of prescriptions in ESRD. Antibiotic selection for the most common
infection sources based on organ systems differed in ESRD vs
non-ESRD (Supplementary Appendix Table 2).
In the SDO, 806 (49.5%) prescriptions came from affiliated
renal providers and 821 (50.5%) from OPs (Table 4). While
both were prescribed at similar frequencies, antibiotic selection
differed. Affiliated renal providers prescribed azithromycin,
amoxicillin, and ciprofloxacin most frequently, while OPs prescribed TMP-SMX, amoxicillin, and amoxicillin-clavulanate
most frequently. SDO renal providers prescribed TMP-SMX
approximately 4 times less frequently than the OPs, whereas
azithromycin was more prescribed. For reference, the antibiotic
selections of the SDO and OPs were compared to the total NYS
ESRD prescriptions, which originated from both renal and outside providers and are included in Table 4.

Table 4. Antibiotic Prescriptions From Small Dialysis Organization Providers Compared to Outside Providers and to End-Stage Renal Disease Data of the
Centers for Medicare and Medicaid Services

Antibiotic
Azithromycin

ESRD, %
(n = 48 100)

SDO, %
(n = 806)

OP, %
(n = 821)

P Value
(ESRD vs SDO)

P Value
(SDO vs OP)

12.71

38.09

10.35

<.001

<.001

Amoxicillin

8.27

13.90

12.67

<.001

.50

Ciprofloxacin

9.98

10.30

8.40

.8

.20

Cephalexin

9.29

7.69

9.01

.1

.40

Levofloxacin

11.32

6.58

10.35

<.001

.008

Amoxicillin-clavulanate

9.69

6.33

10.84

.002

.002

Cefuroxime

2.27

4.09

1.46

<.001

.002

10.38

3.47

13.52

<.001

<.001

Doxycycline

7.71

2.61

7.43

<.001

<.001

Clindamycin

4.20

2.48

3.53

.02

.30

TMP-SMX

Abbreviations: ESRD, end-stage renal disease; OP, outside provider; SDO, small dialysis organization; TMP-SMX, trimethoprim-sulfamethoxazole.
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Figure 1. Range of dosages for trimethoprim-sulfamethoxazole (A) and the fluoroquinolone antibiotics ciprofloxacin (B), moxifloxacin (C), and levofloxacin (D). Abbreviation:
ESRD, end-stage renal disease.

Therefore, these prescription selections may be justified, but
due to the nature of our data, assessing specific details is not
possible. Other limitations include that our data are retrospective and pertain only to NYS and, specifically, those covered
by CMS.
The current study highlights the need for effective antibiotic
stewardship in ESRD with aims in reducing CDI rates as well
MDROs. Resistant infections result in increased morbidity and
mortality [26, 27] and contribute 2 billion dollars per year to
ESRD costs [4, 5]. Benefits of such programs in hospitals include decreasing CDI rates [28] and reducing intensive care
unit antimicrobial costs and consumption [29]. Inappropriate
antibiotic was reduced by 20.5% in long-term care facilities and
by 22%–36% in hospital settings [30]. In 2014 the Centers for
Disease Control and Prevention recommended that all hospitals have antimicrobial stewardship programs.
There are no stewardship programs or clear designs to optimize antibiotic usage specifically for ESRD. Outpatient stewardship programs have used various mechanisms successfully in
restraining antibiotic usage [31] and, therefore, potentially may
be implemented in dialysis units. However, outpatient dialysis
supports a specific population cared for by multiple general and
specialized providers, adding to the complexity and difficulty
of establishing such programs. It would necessitate an educational process involving renal personnel—medical directors,
nephrologists, physician’s assistants, nurse practitioners, technicians, and nurses—but also directed toward primary care, ED,
and urgent care physicians. This is particularly significant, as
physicians underestimate their level of inappropriate antibiotic
use [32]. Importantly, the education process must include the
patient, creating learned consumers who can question capricious antibiotic use and report it to renal providers. Programs
will also need mechanisms of reporting and feedback. If implemented, based on a model analysis that assumed a 20% decrease in antibiotic prescribing, stewardship programs may lead
to cost savings of up to $11 million annually, 4.6% reduction in
mortality, and a 4.8% reduction in infections [5]. Being a modeled estimate derived from assumptions and probabilities, these
findings have limitations [5].
In conclusion, the current study indicating increased antibiotic usage in ESRD suggests that there is a need for antibiotic
stewardship aimed at ESRD patients and their providers. Timely
detection of antibiotic usage would allow for appropriate antibiotic adjustments. Further research may evaluate implementation, feasibility, and effectiveness of an antibiotic stewardship
intervention in decreasing overall antibiotic usage, improving
antibiotic appropriateness, and decreasing morbidity.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online.
Consisting of data provided by the authors to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the authors, so
questions or comments should be addressed to the corresponding author.
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[20–22]. Recently, a prevalence study of IV antimicrobials in
Pennsylvania revealed that almost 60% were inappropriately
prescribed [23]. Few ESRD studies have focused specifically
on oral antibiotics. Rather, emphasis has been on IV antibiotics
[13] or IV combined with oral antibiotics; with the conclusion
that up to 30% are prescribed inappropriately [7].
The greater use of oral antibiotics in ESRD may reflect
the higher incidence of infection diagnoses compared to
non-ESRD patients. Still, >50% of prescriptions were for
absent indications, nonspecific symptoms, or viral illnesses
(Table 3). Although high rates of prescriptions without a diagnosis have previously been demonstrated in the general
public [12], the rate in the ESRD population was significantly
higher compared to the general CMS population (32.4% vs
29.2%; P < .001). This higher rate is especially concerning
due to the greater propensity toward antibiotic-associated
infections in ESRD [5, 9–11].
The aforementioned findings along with longer antibiotic
duration (11.8 vs 9.3 days), questionable selections and their
dosing (TMP-SMX, nitrofurantoin), and questionable indications suggest possible inappropriate prescribing. At very least
it reveals opportunities to improve antibiotic prescribing. For
example, >20% of the antibiotics prescribed in ESRD patients
were fluoroquinolones, which are renally cleared. They have
been associated with hypoglycemia, QT interval prolongation,
interaction with phosphate binders, and mental health side effects [14]—all being risks of particular consequence in ESRD.
In addition, antibiotic selection differed most notably in the
greater frequency of TMP-SMX in the ESRD population, comprising >10% of prescriptions. TMP-SMX with its broad coverage is an attractive choice in unclear diagnoses such as fever
of unknown origin and cellulitis. Its preference may be related
to the increased skin infection diagnoses, possibly treating cutaneous access infections [14]. In fact, 17% of TMP-SMX was
prescribed for skin infections, higher than any other infection. TMP-SMX is not recommended in creatinine clearances
<15 mL/minute due to potential hyperkalemia [14, 24], and in
36% of prescriptions the dose was not halved as recommended
for creatinine clearances of 15–30 mL/minute.
In the SDO sample, affiliated renal practitioners prescribed
antibiotics as often as OPs, but significantly less TMP-SMX.
This suggests that elevated TMP-SMX use seen statewide may
originate from providers not routinely caring for ESRD patients. The comorbidity and dose adjustment challenges in prescribing for ESRD patients may explain differences in antibiotic
selection between types of providers in the SDO sample. In support, a recent study found that inappropriate antibiotic dosing
decreased when primary care physicians co-managed patients
with nephrologists [25].
Diagnoses based on ICD-10 codes may not accurately reflect
the reasoning behind prescriptions and do not allow for relevant clinical details such as organism susceptibility patterns.
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